PIN28 A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.587
https://www.valueinhealthjournal.com/article/S1098-3015(21)00804-4/fulltext
Title :
PIN28 A US Payer Cost-Effectiveness Analysis of Imipenem/Cilastatin/Relebactam Versus Colistin Plus Imipenem/Cilastatin in Patients with Carbapenem-Resistant Bacterial Infections
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00804-4&doi=10.1016/j.jval.2021.04.587
First page :
Section Title :
Open access? :
No
Section Order :
10065